Clinically, Alzheimer's disease (AD) is characterized by dementia of insidious onset;pathologically, it is characterized by the presence of numerous neuritic plaques, neurofibrillary tangles, and a progressive Neurodegeneration. There is exceedingly strong evidence that abnormal assemblies of A? are neurotoxic and have a key role in AD. Why A? is increased and accumulates or induces Neurodegeneration is unclear. However, the mechanisms of plaque formation and neurodegeneration in AD brains are not clear. We recently described (He et al., 2007) that generation of amyloid 2 (A?), the main component of plaques, is inhibited by TNFRI deletion, which reduces BACE1 levels via the NF-:B pathway. However, we demonstrated in vitro (Shen et al., 1997) that, unlike TNFRI, which is the TNF death receptor, TNFRII, protects neurons. To examine the roles of TNFRII in APP processing, we cross-bred AD transgenic APP23 mice, which express mutant APP and form many A? plaques, with TNFRII knockout mice, to generate TNFRII knockout (TNFRII-/-) in APP23 mice (APP23/TNFRII-/-). Our preliminary results demonstrated that APP23/TNFRII-/- mice have more A? plaques and increased A? levels at 12 months of age. Thus, we propose a central hypothesis that modulation of TNF type II receptor activity can alter BACE1, A? production and AD neuropathology via NF-:B-dependent and independent intracellular signaling pathways. We will use the double transgenic mouse model, APP23/TNFRII-/-, to examine whether these mice exhibit earlier AD-like pathology. If so, we will study the mechanisms, such as possible TNFRII mediated BACE1 through new signal transduction pathways by NF-kB dependent and non-NF-kB dependent manner, and how these mechanisms ultimately result in neuroprotection. We believe that successful completion of the experiments will lead to novel therapeutic interventions. The goal of this application is to determine how TNFRII is regulated in neurons and in mouse brains, how it affects the generation of A? and its precursors, and whether increased production of TNFRII may be protective and ameliorate Neurodegeneration and AD-like disease in mice. We expect to identify modulators of TNFRII expression and proteins that interact with TNFRII. We also expect to establish that TNFRII is a major modifier of AD pathogenesis and that increasing TNFRII levels reduces disease. If successful, our findings may provide new targets for the treatment of AD and neurodegeneration.

Public Health Relevance

Neuronal and synaptic losses are the most prominent features in the Alzheimer's disease (AD) brain. AD treatments are presently inadequate, so numerous novel therapy ideas deserve rigorous exploration in the academic and pharmaceutical research communities. Inhibition of tumor necrosis factor and its mediated signal transduction pathway is one potential target area, like TNF type II receptor (TNFRII) for AD treatment. We recently have started a promising clinical trial with a drug inhibiting TNF signal pathway on AD patients, which is FDA approved and NIH awarded. Thus, elucidating the regulatory mechanisms for BACE1 could identify new potential therapeutic targets and therefore diminish possible side effects that could arise by directly targeting BACE1. Neuronal and synaptic losses are the most prominent features in the Alzheimer's disease (AD) brain. AD treatments are presently inadequate, so numerous novel therapy ideas deserve rigorous exploration in the academic and pharmaceutical research communities. Inhibition of tumor necrosis factor and its mediated signal transduction pathway is one potential target area, like TNF type II receptor (TNFRII) for AD treatment. We recently have started a promising clinical trial with a drug inhibiting TNF signal pathway on AD patients, which is FDA approved and NIH awarded. Thus, elucidating the regulatory mechanisms for BACE1 could identify new potential therapeutic targets and therefore diminish possible side effects that could arise by directly targeting BACE1.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG025888-09
Application #
8726251
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Petanceska, Suzana
Project Start
2005-04-01
Project End
2015-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
9
Fiscal Year
2014
Total Cost
$373,667
Indirect Cost
$133,367
Name
Roskamp Institute, Inc.
Department
Type
DUNS #
119173933
City
Sarasota
State
FL
Country
United States
Zip Code
34243
Jocham, Gerhard; Klein, Tilmann A; Ullsperger, Markus (2014) Differential modulation of reinforcement learning by D2 dopamine and NMDA glutamate receptor antagonism. J Neurosci 34:13151-62
Sun, Qiying; Hampel, Harald; Blennow, Kaj et al. (2014) Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. J Alzheimers Dis 41:877-86
Yu, Xiaojun; Du, Tingting; Song, Ning et al. (2013) Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease. Neurology 80:492-5
He, Ping; Cheng, Xin; Staufenbiel, Matthias et al. (2013) Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of ýý-secretase in a mouse model of Alzheimer's disease. PLoS One 8:e55091
Long, Jiangang; He, Ping; Shen, Yong et al. (2012) New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor-?. J Alzheimers Dis 30:545-58
Ewers, Michael; Cheng, Xin; Zhong, Zhenyu et al. (2011) Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. J Alzheimers Dis 25:373-81
Cheng, Xin; Yang, Libang; He, Ping et al. (2010) Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J Alzheimers Dis 19:621-30
Kozikowski, Alan P; Chen, Yihua; Subhasish, Tapadar et al. (2009) Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. ChemMedChem 4:1095-105
He, Ping; Shen, Yong (2009) Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer's disease. J Neurosci 29:6545-57
Xia, Weiming; Yang, Ting; Shankar, Ganesh et al. (2009) A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66:190-9

Showing the most recent 10 out of 14 publications